ArticleRisk management and healthcare policy2022
Impact of Diabetes Mellitus on the Immunity of Tuberculosis Patients: A Retrospective, Cross-Sectional Study.
Article in Risk management and healthcare policy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Immune dysregulation in tuberculosis-diabetes comorbidity: mechanistic and translational insights.Frontiers in immunology · 2026Pooled it
- cAMP-response element binding protein (CREB)-mediated glycolysis enhancement promotes apoptosis of RAW264.7 macrophages infected with BCG under high glucose conditions.BMC microbiology · 2026Article
- East Asia and high-income Asia Pacific burden of diabetes mellitus from 1990 to 2023.iScience · 2026Article
- Single-Cell Immune Atlases to Map Small Extracellular Vesicle Cargo in Tuberculosis-Diabetes Comorbidity: A Narrative Review and Conceptual Roadmap.International journal of molecular sciences · 2026Review
- Integrated multi-omics profiling reveals immune-related biomarkers and regulatory networks for early prediction of tuberculosis in type 2 diabetes mellitus.Frontiers in immunology · 2026Article
- Development and Validation of Early Alert Model for Diabetes Mellitus-Tuberculosis Comorbidity.Microorganisms · 2025Article
- Cost-effective in-house-made whole blood materials for internal quality control in clinical flow cytometry analysis.Analytical and bioanalytical chemistry · 2025Article
- Increased circulating Th17 cells and altered CD4 T cell maturation and differentiation in active tuberculosis with type 2 diabetes: a pilot study.Frontiers in immunology · 2025Article
- Development of a clinical prediction model for poor treatment outcomes in the intensive phase in patients with initial treatment of pulmonary tuberculosis.Frontiers in medicine · 2025Article
- Identification of biomarkers and construction of discriminating model for tuberculosis patients with diabetes mellitus based on proteomics: a cross-sectional study.Frontiers in immunology · 2025Article
- Potency of Hyperbaric Oxygen Therapy on Oral Candidiasis Diabetes Mellitus.European journal of dentistry · 2024Article
- Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective.Exploration (Beijing, China) · 2024Review
- Drug resistance in drug-resistant tuberculosis patients with and without diabetes mellitus: a comparative analysis.BMC infectious diseases · 2024Article
- Construction of novel multi-epitope-based diagnostic biomarker HP16118P and its application in the differential diagnosis of Mycobacterium tuberculosis latent infection.Molecular biomedicine · 2024Article
- Article
- Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study.Infection and drug resistance · 2024Article
- Intersecting epidemics: deciphering the complexities of tuberculosis-diabetes comorbidity.Frontiers in tuberculosis · 2024Review
- Clinical features, immunologic parameter and treatment outcome of Chinese tuberculosis patients with or without DM.Frontiers in medicine · 2024Article
- Comparison of CD4+/CD8+ Lymphocytic Subpopulations Pre- and Post-Antituberculosis Treatment in Patients with Diabetes and Tuberculosis.Pathogens (Basel, Switzerland) · 2023Article
- Impact of diabetes itself and glycemic control status on tuberculosis.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) is an infectious disease that poses a significant health threat and is one of the leading causes of death worldwide. Diabetes mellitus (DM) has high morbidity and mortality rates. Previous studies have reported that comorbidities can influence one another and aggravate immune disorders. A systematic and comprehensive evaluation of the immune status of patients with TB and DM (TB-DM) is helpful for early clinical immune intervention and for promoting the recovery of patients with TB-DM. Methods: This study included 159 patients with TB without DM (TB-NDM) and 168 patients with TB-DM. Interferon-γ (IFN-γ) release assays (IGRAs) and TB-specific antibodies against 38kD+16kD proteins were used to detect humoral and cellular immune responses. Flow cytometry was used to analyze the absolute counts of the lymphocyte subsets. Results: There was no significant difference in the positive rate of enzyme-linked immunospot (ELISPOT) assays, enzyme linked immunosorbent assay (ELISA), and 38kD+16kD antibodies between the TB-DM and TB-NDM groups. Pulmonary lobe lesion and cavity formation rates were significantly higher in patients with TB-DM with poor glycemic control than patients with TB-NDM and TB-DM with normal glycemic control. The absolute counts of T lymphocytes, CD8+ T lymphocytes, and B lymphocytes in patients with TB-DM were markedly lower than those in patients with TB-NDM. The absolute counts of T lymphocytes and CD8+ T lymphocytes in patients with TB-DM and hyperglycemia were lower than those in patients with euglycemia. Linear regression analysis revealed that the absolute counts of total T lymphocytes, CD8+ T lymphocytes, and NK cells in patients with TB-DM significantly decreased with increasing fasting blood glucose (FBG) levels. Conclusion: Hyperglycemia is a risk factor for pulmonary cavity formation and lobe lesions in patients with TB-DM and suppresses the absolute counts of total T lymphocytes, CD8+ T lymphocytes, and NK cells in patients with TB-DM. The potential mechanism may involve the downregulation of innate and adaptive immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.